培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的疗效比较

周　娟; 贲素琴

doi:10.3969/j.issn.1007-3969.2015.09.005

您当前的位置：

首页 >

文章列表页 >

培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的疗效比较

更新时间：2025-12-31

- 培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的疗效比较
- The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma
- 中国癌症杂志 2015年25卷第9期页码：671-676
- 作者机构：
  
  1. 南通大学附属医院呼吸科,江苏,南通,226001
  2. 上海市第一人民医院呼吸科,上海,200080
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.09.005
  中图分类号：
- 网络出版：2015-12-15，
  
  纸质出版：2015-12-15
- 稿件说明：
移动端阅览
周　娟,贲素琴. 培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的疗效比较[J]. 中国癌症杂志, 2015, 25(9): 671-676.

周　娟, 贲素琴. The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma[J]. China Oncology, 2015, 25(9): 671-676.
周　娟,贲素琴. 培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的疗效比较[J]. 中国癌症杂志, 2015, 25(9): 671-676. DOI： 10.3969/j.issn.1007-3969.2015.09.005.

周　娟, 贲素琴. The clinical effects of pemetrexed or docetaxel combined with cisplatin as the first line treatment for advanced lung adenocarcinoma[J]. China Oncology, 2015, 25(9): 671-676. DOI： 10.3969/j.issn.1007-3969.2015.09.005.

摘要

背景与目的：目前，晚期肺腺癌主要依靠以化疗为主的综合治疗。培美曲塞作为一种多靶点抗叶酸制剂，与铂类药物联合应用治疗晚期肺腺癌，因其疗效好、不良反应轻而受到推崇。本研究比较培美曲塞与多西他赛联合铂类一线治疗晚期肺腺癌的效果及不良反应。方法：将50例晚期肺腺癌患者随机分为培美曲塞＋顺铂(PC)组和多西他赛＋顺铂(TP)组。每组各25例患者。PC组：培美曲塞500 mg/m

静脉滴注，第1天；顺铂75 mg/m

静脉滴注，第1天。TP组：多西他赛75 mg/m

静脉滴注，第1天；顺铂75 mg/m

静脉滴注，第1天。两组1个周期均为21 d。比较两组的有效率(response rate，RR)、疾病控制率(disease control rate，DCR)、无进展生存期(progression-free survival，PFS)和总生存期(overall survival，OS)。测定外周血T淋巴细胞亚群活性，评价两组患者免疫功能。结果：50例患者均可评价疗效及不良反应，两组均无完全缓解(complete remission，CR)病例，部分缓解(partial remission，PR)20例，疾病稳定(stable disease，SD)17例，疾病进展(progressive disease，PD)13例。PC组与TP组的RR、DCR、PFS和OS差异均无统计学意义(P0.05)。PC组治疗后与TP组相比，CD3

＋

、CD4

＋

、CD4

＋

/CD8

＋

T细胞和NK细胞活性均升高，CD8

＋

T细胞活性降低，但差异无统计学意义(P＞0.05)。两组的不良反应主要为骨髓抑制和消化道反应，PC组Ⅲ~Ⅳ级不良反应白细胞减少、血小板减少、消化道症状和乏力的发生率低于TP组，差异有统计学意义(P0.05)。结论：培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的临床疗效相当，但前者可降低不良反应发生率。

Abstract

Background and purpose: At present

the advanced lung adenocarcinoma is mainly treated by chemotherapy-oriented comprehensive therapy. Pemetrexed as a multi-target antifolate chemotherapeutic drug

combined with platinum

was approved for treatment of advanced lung adenocarcin

oma because of its low toxicity and high efficacy. The purpose of this study was to compare the short-term clinical efficacy and toxicity of pemetrexed and docetaxel combined with cisplatin for advanced lung adenocarcinoma. Methods: Fifty patients with stage Ⅲ-Ⅳ lung adenocarcinoma were randomly divided into two groups. Group PC received pemetrexed (500 mg/m

d1) combined with cisplatin (75 mg/m

d1) and group TP received docetaxel (75mg/ m

d1) combined with cisplatin (75 mg/m

d1) treatment. One cycle was 21 days in both two groups. The response rate (RR)

disease control rate (DCR)

progressionfree survival (PFS) and overall survival (OS) of the two groups were compared. The peripheral blood T lymphocyte subsets and natural killer (NK) cell activity of patients in both groups were measured before and after the treatment

while compared with healthy controls (25 cases). Results: Among 50 patients

no one got complete remission (CR)

20 patients got partial remission (PR)

17 patients had stable disease (SD) and 13 patients had progressive disease (PD). It showed no significant difference in RR

DCR

PFS and OS (P0.05) between two groups. Compared with group TP

the activity of CD3

CD4

/CD8

T cells and NK cells increased and CD8

T cells reduced in group PC after treatment

but the value had no obvious change (P0.05). The common side effects were hematological toxicity and gastrointestinal response. The incidence of side effects in group PC was lower than that in group TP

and the degree was also slighter (P0.05). Conclusion: The clinical efficacy of pemetrexed combined with cisplatin is equal to docetaxel combined with cisplatin in treatment of advanced lung adenocarcinoma

but the former could reduce the adverse reaction rate.

关键词

Keywords

references

浏览量

1994

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

PD-L1表达对晚期肺腺癌患者培美曲塞化疗效果的影响及其机制

周剂量多西他赛联合顺铂与周剂量多西他赛联合奥沙利铂治疗晚期胃癌的临床研究

鞘内注射培美曲塞联合程序性死亡蛋白-1抑制剂治疗实体瘤脑膜转移的Ⅰ期临床研究

化疗相关腹泻全程管理中国专家共识（2025年版）

卡瑞利珠单抗联合化疗及靶向治疗在复发、转移及初治晚期宫颈癌中的疗效与安全性分析：一项回顾性队列研究